DOES BMI/BSA AFFECT STEM CELL MOBILISATION?: SINGLE CENTRE EXPERIENCE
Hematology, Transfusion and Cell Therapy · 2024-12 · 46 · S60-S61
DOI: 10.1016/j.htct.2024.11.052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematology, Transfusion and Cell Therapy, 2024-12. Verfasst von Seda Yılmaz und 3 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Mobilisation
Abstract (Originalsprache)
Haematopoietic stem cell transplantation is accepted as an important treatment strategy in the treatment of many haematological diseases including acute leukaemia, lymphoma, multiple myeloma as well as sickle cell anaemia and beta thalassaemia major. BMI is an important factor affecting the donor's response to mobilisation and thus haematopoietic progenitor cell yield. This effect is thought to be due to the relatively high dose of filgrastim administered to donors with higher BMI or to the presence of unknown intrinsic factors affecting mobilisation related to the amount of adipose tissue in each donor. In studies examining the relationship between obesity and CD34, negative effects of BMI on the number of progenitor cells have been shown. A total of 41 patients, including 32 patients and 9 healthy donors, who underwent stem cell mobilisation for bone marrow transplantation in the therapeutic apheresis unit of Konya City Hospital between 10/2023 and 8/2024 were included in our study. The effects of disease diagnosis, age, number and content of chemotherapy, radiotherapy history, body surface area (BSA), body mass index (BMI), chronic habits such as smoking and alcohol, comorbidity and vitamin D level on stem cell mobilisation were investigated. In our study, data of 9 healthy donors, 21 multiple myeloma and 11 lymphoma patients were analysed. Median age was 61 (18-72) years, 46.3% (19) were female and 53.7% (22) were male. There was a history of radiotherapy in 9.8% of the patients. While 46.3% of the patients were mobilised with cyclophosphamide+filgrastim, 41.5% with filgrastim, 4.9% with other chemotherapeutic agents+ filgrastim, 4.9% with filgrastim+plerixafor, 2.4% of the patients had stem cell collection by harvest procedure. On day 1 of stem cell mobilisation, there was no difference between those who collected sufficient CD34 positive stem cells and those who failed in terms of gender, height, weight, BMI, BSA, chronic habits, presence of comorbidities, vitamin D level and number of chemotherapy received. There was no statistically significant correlation between the total amount of CD34 positive stem cells and gender, height, weight, BMI, BSA, chronic habits, presence of comorbidities, vitamin D level and number of received chemotherapy. A negative, strong and statistically significant correlation was found between the number of CD34 positive stem cells and BMI in multiple myeloma patients (rho: -0.705 p
Zitieren
APA
Yılmaz, S., Günay, A., Cırık, S., & Baştürk, A. (2024). DOES BMI/BSA AFFECT STEM CELL MOBILISATION?: SINGLE CENTRE EXPERIENCE. Hematology, Transfusion and Cell Therapy, 46, S60-S61. https://doi.org/10.1016/j.htct.2024.11.052
Vancouver
Yılmaz S, Günay A, Cırık S, Baştürk A. DOES BMI/BSA AFFECT STEM CELL MOBILISATION?: SINGLE CENTRE EXPERIENCE. Hematology, Transfusion and Cell Therapy. 2024;46:S60-S61. doi:10.1016/j.htct.2024.11.052
BibTeX
@article{Ylmaz2024,
author = {Yılmaz, Seda and Günay, Ayşe and Cırık, Salih and Baştürk, Abdulkadir},
title = {DOES BMI/BSA AFFECT STEM CELL MOBILISATION?: SINGLE CENTRE EXPERIENCE},
journal = {Hematology, Transfusion and Cell Therapy},
year = {2024},
volume = {46},
pages = {S60--S61},
doi = {10.1016/j.htct.2024.11.052}
}
EUVIMED